← Back
Data updated: Mar 29, 2026
IPSEN
OncologyGastroenterologyNeurology
Pharma
IPSEN is a pharmaceutical company focused on Oncology, Gastroenterology, Neurology. Key products include BYLVAY.
2005
Since
5
Drugs
-
Trials
6
Approved (2yr)
Key Drugs
Top Drug Revenues Pro
Loading...
Revenue Over Time Pro
Loading...
Competitive Matchups Pro
Loading...
Loading...
Recent Activity
BYLVAY 2025-12-19
Efficacy
INCRELEX 2025-07-09
Labeling
BYLVAY 2025-03-20
Labeling
SOHONOS 2025-03-13
Efficacy
ONIVYDE 2024-12-23
Labeling
IQIRVO 2024-06-10
Type 1 - New Molecular Entity
SEC Filings
Pro
Loading...
Therapeutic Areas
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Oncology 67%
1 drugs Phase 3: 6 Phase 2: 5 Phase 1: 10
Gastroenterology 20%
1 drugs Phase 3: 1 Phase 2: 1 Phase 1: 3
Neurology 13%
0 drugs Phase 3: 2 Phase 2: 1
Pipeline Forecast
Loading...
Loading...
Upcoming Trial Milestones Pro
Loading...
Patent Cliff Pro
Loading...
Loading...
Loading...